TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01506349

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: gluten
Description: 4 grams of gluten.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT01451541

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclesonide nasal aerosol 37 mcg
Description: ciclesonide nasal aerosol 37mcg - the dose is administered as 1 actuation per nostril to give a total dose of 37

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ciclesonide nasal aerosol 74 mcg
Description: ciclesonide nasal aerosol 74 mcg - the dose is administered as 1 actuation per nostril to give a total dose of 74 mcg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo - one dose per nostril
Study: NCT01799850

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: pioglitazone 30 mg daily, pill, eight weeks, placebo randomly assigned

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo assigned randomly, double blind
Study: NCT05778890

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention Group: Physiotherapy program + home exercises program
Description: Physiotherapy program: The physiotherapy program consisted of 1 session per day for 3 weeks, a total of 15 sessions. Treatment for control group included Ultrasound for 5 minutes to both TMJ, TENS on both TMJ for 20 minutes, exercise for 30 minutes and patient education. In addition to the treatment for control group, intervention group received home exercises program.The intervention group was also taught home exercises program and asked to do 6 repetitions 6 times a day. This exercise program was given to the patients in brochure form.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group : Physiotherapy program
Description: Physiotherapy program: The physiotherapy program consisted of 1 session per day for 3 weeks, a total of 15 sessions. Treatment for control group included Ultrasound for 5 minutes to both TMJ, TENS on both TMJ for 20 minutes, exercise for 30 minutes and patient education.
Study: NCT01634685

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiation therapy will be administered daily, Monday-Friday, for a total of 28 treatments, delivered at 1.8 Gy/fraction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bavituximab
Description: Bavituximab will be delivered concurrently with the radiation therapy for 6 weeks (one time each week), followed by 2 weeks of bavituximab administration by itself.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: capecitabine, will be delivered twice daily p.o. on the days of radiation treatment, at a dose of 825 mg/m2.
Study: NCT02701101

Intervention type: DEVICE
Group type: OTHER
Intervention: Use of SEM200 Scanner daily
Description: From enrollment to exit,daily SEM Scanner readings collected on Sacrum and Heels

Intervention type: OTHER
Group type: OTHER
Intervention: Assessment and treatment of Pressure Ulcers using SOC
Description: Nurse review of Skin risk and skin assessment, notes in chart to assess the frequency to turn patient, use of a specialist bed to prevent or treat early pressure ulcers
Study: NCT02117336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P1446A-05
Description: The study have dose escalation phase, followed by a dose extension phase.~* Dose escalation phase: five Dose Levels will be evaluated in the 'dose escalation' phase. The Dose Levels selected are 50 mg (Dose Level 1), 75 mg (Dose Level 2), 125 mg (Dose Level 3), 200 mg (Dose Level 4) and 275 mg (Dose Level 5), once daily. If required, a 25 mg once daily dose (Dose Level -1) will also be studied. For Dose Levels 1, 2 and 3 there will be 2- dosing periods: Single Dose and Continuous Dose. At least 3-patients will be enrolled at each Dose Level. Dosing regimens planned for Dose Level 4 and 5 are 200 and 275 mg once daily. In the continuous dose period, patients will receive P1446A-05 on a 28-day cycle, until the occurrence of disease progression or unacceptable toxicity.~* Dose Extension Phase: Up to a total of 14 patients will be treated at the MTD of P1446A-05, determined in the dose escalation phase, until the occurrence of disease progression or unacceptable toxicity or death.
Study: NCT04838093

Intervention type: DIAGNOSTIC_TEST
Intervention: PCR
Description: Nasal or pharyngeal respiratory swabs were routinely taken of each patient admitted at our departments and repeated regularly at 48 h intervals during the inpatient stay.~In the HCP cohort testing for SARS-CoV-2 RNA was performed, on a weekly basis, at the Department of Laboratory Medicine, Medical University of Vienna, Austria, using real-time polymerase chain reaction (RT-PCR). Comparability of the results of all test methods used was confirmed by participation in international quality control ring trials.

Intervention type: DIAGNOSTIC_TEST
Intervention: PCR
Description: Nasal or pharyngeal respiratory swabs were routinely taken of each patient admitted at our departments and repeated regularly at 48 h intervals during the inpatient stay.~In the HCP cohort testing for SARS-CoV-2 RNA was performed, on a weekly basis, at the Department of Laboratory Medicine, Medical University of Vienna, Austria, using real-time polymerase chain reaction (RT-PCR). Comparability of the results of all test methods used was confirmed by participation in international quality control ring trials.

Intervention type: DIAGNOSTIC_TEST
Intervention: PCR
Description: Nasal or pharyngeal respiratory swabs were routinely taken of each patient admitted at our departments and repeated regularly at 48 h intervals during the inpatient stay.~In the HCP cohort testing for SARS-CoV-2 RNA was performed, on a weekly basis, at the Department of Laboratory Medicine, Medical University of Vienna, Austria, using real-time polymerase chain reaction (RT-PCR). Comparability of the results of all test methods used was confirmed by participation in international quality control ring trials.
Study: NCT02209207

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill
Study: NCT04215991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefiderocol
Description: Administered intravenously over 3 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefiderocol
Description: Administered intravenously over 3 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of care administered will be selected by the investigator based on the suspected or confirmed pathogen(s) for the infection in accordance with local standards.
Study: NCT02209207

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: walking training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: walking training
Study: NCT04215991

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of care administered will be selected by the investigator based on the suspected or confirmed pathogen(s) for the infection in accordance with local standards.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of care administered will be selected by the investigator based on the suspected or confirmed pathogen(s) for the infection in accordance with local standards.
Study: NCT01237964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xiaflex (FDA approved collagenase)
Description: 0.58mg of collagenase will be diluted in saline and injected in 3 points surrounding the limiting contracture
Study: NCT01213550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo mouthrinse
Study: NCT06437990

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arteriovenous loop graft
Description: Using saphenous vein graft to create an arteriovenous loop from the common carotid artery to the external jugular vein, providing vascular supply for a free functional gracilis muscle flap in patients with late-onset brachial plexus injury with concomitant subclavian or axillary artery injury.
Study: NCT02511574

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: natural progesterone

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cervical pessary
Study: NCT02310633

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Memory Strategy Training
Description: This intervention involves intervention that teaches participants to use active encoding strategies to learn and remember new information. The intervention will be implemented using verbal and face-name paired associate learning.
Study: NCT03187756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Shortened duration immunosuppression following nonmyeloablative peripheral blood stem cell transplant with high dose post transplantation cyclophosphamide in malignancies to engraft.
Study: NCT02310633

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Errorless Learning
Description: This intervention enhances consolidation of correct target information by preventing false recall of incorrect information during the acquisition phase. Participants are encouraged to recall target information only if they are sure it is correct, thus eliminating errors. The intervention will be implemented using verbal and face-name paired associate learning.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Retrieval Practice
Description: This intervention enhances retrieval of correct target information by actively practicing retrieval in the presence of a cue. The intervention will be implemented using verbal and face-name paired associate learning.
Study: NCT04317482

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard social stress task
Description: Participants will be asked to respond in detail to three scenarios. This is a standard social stressor task. Participants may be prompted by an experimenter. However, the participant will receive no verbal nor nonverbal feedback.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Stressful experience in the ED
Description: Participants will be asked to imagine and then describe both feelings and bodily sensations experienced at their most stressful ED visit, in order to help them more fully re-experience the situation. In this regard, the second condition is more similar to stress imagery employed by Sinha et al, which elevated cortisol to a greater degree than a social stressor task. Participants may be prompted by an experimenter. However, the participant will receive no verbal nor nonverbal feedback.
Study: NCT00595283

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Child Interaction Therapy-Emotion Development (PCIT-ED)
Description: PCIT-ED includes fourteen 1-hour therapy sessions over 14 weeks. Sessions will focus on positive parent-child interactions skills, ways to manage emotions, and relaxation techniques.
Study: NCT02911363

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Captivator cassette
Description: The Captivator tissue cassette has an effect on the preservation of tissue histology.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: The specimen will be processed following the College of American Pathology Standards.
Study: NCT03863444

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prenatal Preparation Education
Description: Intervention, provided by researchers, includes video, counseling, and skill practices. Video contains (1) Newborn Reaction, including rooting reflex, correct latch-on posture, assuring newborn having enough milk intakes; (2) Newborn Care, including holding, dipper-changing, clothes-changing, and swaddle the newborn; and (3) Partner Support, including the importance of partner support and the content how partner provide support to the postpartum women. After watching the video, the researcher will provide participants counseling, and then each pair of participants will have skill practice.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine care
Description: Routine care, provided by clinic nurses, includes antenatal breastfeeding education (i.e., providing education sheet, explaining the benefits and importance of breastfeeding, exclusive breastfeeding for six months, responsive breastfeeding, maintaining milk production, immediately skin-to-skin touch after delivery, and room-in) and demonstration of newborn care (i.e., newborns holding posture, breastfeeding holding posture, and newborn latch-on posture) by pictures and baby models.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine care
Description: Routine care, provided by clinic nurses, includes antenatal breastfeeding education (i.e., providing education sheet, explaining the benefits and importance of breastfeeding, exclusive breastfeeding for six months, responsive breastfeeding, maintaining milk production, immediately skin-to-skin touch after delivery, and room-in) and demonstration of newborn care (i.e., newborns holding posture, breastfeeding holding posture, and newborn latch-on posture) by pictures and baby models.
Study: NCT01797029

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SIIL Live Attenuated Influenza Vaccine
Description: A single dose of SIIL Trivalent LAIV--2012/2013 Northern Hemisphere vaccine containing A/California/7/2009 (H1N1), A/Victoria/361/2011 (H3N2), B/Wisconsin/1/2010

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single dose of inactive placebo will be identical to reconstituted SIIL LAIV in ingredients and concentrations except A/California/7/2009 (H1N1), A/Victoria/361/2011 (H3N2), B/Wisconsin/1/2010 will be replaced with egg allantoic fluid.
Study: NCT01326598

Intervention type: DEVICE
Intervention: V-Go™
Description: Use of Insulin Delivery Device, V-Go, and the effect on A1C for T2DM patients in five categories of baseline oral antidiabetes drug (OAD) use with or without insulin.
Study: NCT02183467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1356, low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1356, high dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Study: NCT01753752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chitosan- N- Acetylcysteine eye drops

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01707823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetylsalicylic acid
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01144689

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Training
Description: 8 sessions of behavioral treatment for smoking cessation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Cessation Therapy
Description: 8 sessions of behavioral treatment for smoking cessation
Study: NCT00595283

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Developmental Education Parenting Intervention (DEPI)
Description: DEPI includes 14 weekly, 1-hour education sessions covering a range of child development and parenting topics. Classes are in a small group format and will emphasize emotional and social development.
Study: NCT04522921

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Diet high on protein (25E%/day)
Description: In a caloric restricted and increased physical activity setting, the control group will consume a low-moderate protein (15E%/day) diet whereas the intervention group will consume a higher protein (25E%/day) diet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Increased follow-up contact after attending a weight loss camp
Description: After leaving the camp, the children and their families with increased follow-up contact will be contacted once every month within the first 6 month and once every other month until 52-weeks follow-up (8 times total). The children and their families will be contacted by phone, facetime or skype as they prefer, within a predetermined and known timeframe. The conversation will focus on individual topics chosen by the child/parent.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Increased follow-up contact after attending a weight loss camp
Description: After leaving the camp, the children and their families with increased follow-up contact will be contacted once every month within the first 6 month and once every other month until 52-weeks follow-up (8 times total). The children and their families will be contacted by phone, facetime or skype as they prefer, within a predetermined and known timeframe. The conversation will focus on individual topics chosen by the child/parent.
Study: NCT03713645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus Extended Release Oral Tablet [Envarsus] 0.13mg/kg/day initiated within post-operative day 3 after kidney transplant
Description: Study drug (tacrolimus extended-release) initiated at 0.13/mg/kg/day for all patients
Study: NCT00333138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTY720
Description: FTY720 capsule was taken orally once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTY720
Description: FTY720 capsule was taken orally once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1.25 mg capsule was given once daily
Study: NCT01443143

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Portion-controlled diet
Description: During this diet period, participants will consume portion-controlled products from the Nutrisystem-D program for three entrees and one (women) or two (men) snacks per day. These pre-packaged portion-controlled items will be supplemented with grocery additions (fruits, vegetables, and low-fat dairy items) to provide approximately 1300 (women) to 1500 (men) calories per day. The Nutrisystem-D program (i.e., provided foods plus grocery additions) provides approximately 53% of calories from carbohydrate, 22% of calories from fat (6% from saturated fat and 0% from trans fat), and 25% of calories from protein. Women and men on the program consume approximately 1800 and 2000 mg/d, respectively, of sodium, and 31 and 35 g/d, respectively, of fiber.

Intervention type: DIETARY_SUPPLEMENT
Group type: NO_INTERVENTION
Intervention: Usual Diet
Description: During the usual diet period, participants will not be given any specific instructions about what they should or should not consume. Instead, they will be told to Eat how you would normally eat if you were not in this study.
Study: NCT04124822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piroxicam 20 mg
Description: Piroxicm is from oxicam family of anti inflammatory drug that inhibits prostaglandin synthesis and effectively lower pain threshold levels

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisolone 20 mg
Description: prednisolone is from steroid family of anti inflammatory drug that inhibit arachidonic acid and effectively lowers the pain
Study: NCT03528044

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Description: In this study, patients will undergo sleeve gastrectomy to reduce the size of the stomach to induce weight loss.
Study: NCT03729869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: 200 mg of exogenous progesterone twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: 200 mg of exogenous progesterone twice a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One dose of matched placebo twice a day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One dose of matched placebo twice a day.
Study: NCT00336193

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home visitation
Description: Home visitation to improve maternal health and well-being and parenting practices
Study: NCT03444363

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser group
Description: Laser application in addition to SRP

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Placebo laser application in addition to SRP
Study: NCT03819283

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Hepatic evaluation
Description: Evaluation of hepatic steatosis and fibrosis by non invasive tests, either serum markers (steatotest, Fibrotest) or imaging methods (CAP, FibroScan)
Study: NCT03260335

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anxiety management strategy
Description: Anxiety management strategy as per standard care plan
Study: NCT03191396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Dose gradually increased to 1.0 mg, given s.c. (under the skin), once-weekly for 30 weeks. Participants will remain on their pre-study anti-diabetic drugs (tablets), if any

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Dose gradually increased to 1.2 mg, given s.c. once-daily for 30 weeks. Participants will remain on their pre-study anti-diabetic drugs, if any
Study: NCT01025245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remifentanil, MgSO4
Description: Patients undergoing thyroidectomy will be randomly assigned to one of three groups. Remifentanil will be infused intraoperatively at 0.05 ㎍/㎏/min (group Ⅰ) or 0.2 ㎍/㎏/min (group Ⅱ \& Ⅲ). Patients in group Ⅲ will be received 30 ㎎/㎏ MgSO4 at the induction of general anesthesia followed by a maintenance infusion of 10 ㎎/㎏/hr intraoperatively until skin closure.
Study: NCT02508701

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Message X Onsite/Offsite Vaccination
Description: Personal, Altruistic Message vs Generic Message Inside-Dormitory Vaccination vs. Student Health Center Vaccination

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Message X Onsite/Offsite Vaccination
Description: Personal, Altruistic Message vs Generic Message Inside-Dormitory Vaccination vs. Student Health Center Vaccination

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Message X Onsite/Offsite Vaccination
Description: Personal, Altruistic Message vs Generic Message Inside-Dormitory Vaccination vs. Student Health Center Vaccination

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Message X Onsite/Offsite Vaccination
Description: Personal, Altruistic Message vs Generic Message Inside-Dormitory Vaccination vs. Student Health Center Vaccination
Study: NCT00651118

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azelastine Hcl
Description: azelastine Hcl 548 mcg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azelastineHcl / fluticasone propionate
Description: azelastine Hcl 548 mcg / fluticasone propionate 200 mcg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone propionate
Description: fluticasone propionate 200 mcg